Compare Fifth Third Bancorp Common Stock (FITB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fifth Third Bancorp Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Fifth Third Bancorp Common Stock trades at $50 (market cap $45.54B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Fifth Third Bancorp Common Stock is far larger — about 9.3× Travere Therapeutics Inc. Common Stock's market cap, and Fifth Third Bancorp Common Stock pays a 3.35% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FITB | TVTX | |
|---|---|---|
Market Cap | $45.54B | $4.88B |
Volume | 4,742,681 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $59.37 | $67.52 |
52-Week Low | $40.36 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $63.41B | $5.01B |
Dividend Yield | 3.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fifth Third Bancorp (FITB) trades at $50.22, down 1.18% with bearish technical signals from moving averages. The stock shows solid fundamentals with a 22.36% net income margin and has beaten earnings expectations in two of the last three quarters. Recent news highlights the bank's innovation banking launch and Q3 guidance tracking at the high end of ranges post-Comerica conversion. Analyst consensus remains strongly positive with a $62.63 price target representing 25% upside potential.
FITB presents a compelling value opportunity with reasonable valuation multiples (P/E 16.91, P/B 1.41) and strong profitability metrics. Key risks include regulatory scrutiny of banking practices and integration challenges from the Comerica acquisition. The upcoming Q3 earnings report on October 19 will be crucial for validating the bank's growth trajectory and capital management strategy.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fifth Third Bancorp Common Stock
Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.
Read more on FITB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
